Stefania Morganti

Nov 21, 2024 | oncologynewscentral.com | Stefania Morganti

The National Cancer Institute defines minimal residual disease (MRD) as the very small number of cancer cells that remain in the body during or after treatment. The term MRD, which has been in use for more than 40 years, was first introduced by hematologists to describe the strong association between MRD detection after treatment and the risk for relapse.

Oct 9, 2024 | nature.com | Naiara Perurena |Yoona Yang |Carrie Rodriguez |Alycia Gardner |Patrick Loi |Yilin Xu | +9 more

AbstractTriple-negative breast cancer (TNBC) is the most aggressive breast cancer subtype and has the highest rate of recurrence1. The predominant standard of care for advanced TNBC is systemic chemotherapy with or without immunotherapy; however, responses are typically short lived1,2. Thus, there is an urgent need to develop more effective treatments. Components of the PI3K pathway represent plausible therapeutic targets; more than 70% of TNBCs have alterations in PIK3CA, AKT1 or PTEN3,4,5,6.

Mar 21, 2024 | jamanetwork.com | Stefania Morganti |Antonio Marra |Federico II

Abstract Importance  Poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors have revolutionized the treatment of patients with germline BRCA1/2-associated breast cancer, representing the first targeted therapy capable of improving outcomes in patients with hereditary tumors. However, resistance to PARP inhibitors occurs in almost all patients.

Feb 22, 2024 | espanol.medscape.com | Maurie Markman |Pavani Chalasani |Stefania Morganti

Autores y Conflictos de interés Dr. Maurie Markman Profesor Clínico de Medicina, Drexel University College of Medicine; Presidente, Medicine & Science, Cancer Treatment Centers of America, Filadelfia, Pennsylvania, Estados UnidosEl Dr. Maurie Markman ha declarado las siguientes relaciones económicas pertinentes:Ha recibido ingresos por un importe igual o superior a 250 dólares de: Genentech, Inc.; AstraZeneca Pharmaceuticals LP; Celgene; Clovis; Amgen Dra. Pavani Chalasani, M. P. H.

Feb 6, 2024 | reference.medscape.com | Winston Tan |Stefania Morganti |Maurie Markman

Authors and Disclosures Winston W. Tan, MD Associate Professor of Medicine, Mayo Medical School; Consultant and Person-in-Charge of Genitourinary Oncology-Medical Oncology, Division of Hematology/Oncology, Department of Internal Medicine, Mayo Clinic; Vice Chairman of Education, Division of Hematology/Oncology, Mayo Clinic, Jacksonville, FloridaDisclosure: Winston W. Tan, MD, has disclosed no relevant financial relationships.